This information is intended for media professionals and investors
|Medtronic Media Contacts:
Public and Media Relations ,
+44 1923 212 213
Vision 3D Implantable Cardiac Devices Now On Medtronic Carelink Network
European Patients Benefit from Wireless Remote Monitoring with Latest Therapies
MINNEAPOLIS, USA and NICE, FRANCE – 19 June 2008 – Today at Cardiostim 2008, Medtronic, Inc. (NYSE: MDT) announced that all Vision 3D™ implantable cardioverter-defibrillators (ICDs) and cardiac resynchronisation therapy-defibrillators (CRT-Ds) are now compatible with the Medtronic CareLink® Network. More than 250,000 patients at 2,400 clinics in 20 countries currently are followed remotely via the Medtronic CareLink Network, which allows physicians to perform a complete analysis of all the device- and patient-specific cardiac data stored within Medtronic implantable cardiac devices. With this announcement, all current models of Medtronic ICDs, CRT-Ds and pacemakers are compatible with the Medtronic CareLink Network, which has registered more than 1 million patient data transmissions since its inception.
“Medtronic offers the breadth of pacemaker and ICD therapies, deep and varied product lines, and geographic reach of the CareLink Network for remotely monitoring patients with Medtronic cardiac devices,” said Oern Stuge, president of Europe and Central Asia for Medtronic. “With the addition of Vision 3D devices on the Network, European physicians and patients can have increased confidence in the effectiveness of therapy delivery as well as wireless alerting capabilities for conditions such as worsening heart failure via CareAlert notifications.”
The Medtronic CareLink Network helps physicians and patients better manage chronic cardiovascular disease treated by implantable device therapy. It enables the transmission of patient and implanted device data using a portable monitor. Within minutes, the patient’s physician and nurses can view the data on a secure Internet Web site.
• For heart failure patients with Medtronic devices equipped with Conexus® Wireless Telemetry – all Vision 3D ICDs and CRT-Ds, as well as Concerto® CRT-Ds or Virtuoso® ICDs – a Medtronic CareAlert™ Notification can be sent via the Medtronic CareLink Network to physicians wirelessly and automatically, providing timely insight into a patient’s changing disease condition and the potential for treatment decisions before the condition worsens.
• The transmitted information, which is comparable to that provided during an in-clinic device follow-up visit, provides the physician with a view of how both the device and patient’s heart are operating.
• The system provides an efficient, safe and convenient way for specialty physicians to remotely monitor the condition of their patients and, if needed, make adjustments to medication or prescribe additional therapy.
• It also saves patients time by potentially eliminating some in-office visits.
The Company also announced today that several pacemaker models have been added for remote device data transmission via the Medtronic CareLink Network in the European market:
• Adapta® portfolio, including the Adapta®, Versa® and Sensia® pacemakers;
• EnRhythm® pacemakers;
• EnPulse® pacemakers; and
• Kappa® 600, 700, 800, 900 pacemakers
The Adapta portfolio offers physicians and patients the convenience of automaticity, and Medtronic offers its remote monitoring service for its full line of current pacemakers in many countries around the world. Additionally, data from the Medtronic-supported PREFER trial was presented recently that showed remote monitoring of pacemaker patients via the Medtronic CareLink Network detected clinically actionable events (CAEs) more quickly than routine follow-up care of transtelephonic monitoring (TTM) and in-office visits.
About Vision 3D
Medtronic’s Vision 3D devices are the industry’s first with several exclusive features: ATP (anti-tachycardia pacing) During Charging™, which automatically uses pacing pulses to painlessly stop fast, dangerous heartbeats, while concurrently preparing to deliver a shock if needed, with no delay; MVP® mode, or Managed Ventricular Pacing, which allows doctors to dramatically reduce unnecessary pacing to the right ventricle (RV, or the heart’s lower chamber) in all Vision 3D ICDs; and some devices also include OptiVol® Fluid Status Monitoring. OptiVol’s ability to manage fluid status over time can provide physicians with important insights in conjunction with ongoing monitoring of other patient symptoms. An additional benefit for European patients with OptiVol is when fluid in the heart and lung cavity exceeds a programmable threshold, a CareAlert can be sent to the physician; early detection of this fluid build-up gives the clinician the opportunity to intervene, potentially preventing cardiac decompensation and avoiding patient hospitalisation.
Additionally, some Vision 3D CRT-D devices feature automaticity with Complete Capture Management™, which improves patient safety by continuously and automatically adjusting to changing patient needs. Complete Capture Management also provides flexibility for clinicians so they may eliminate certain manual checks and devote more time to patients, procedures and complex cases.
These proprietary features, coupled with the industry-leading Medtronic CareLink Network, offer physicians choices for different clinical situations.
“Continuous remote monitoring of Vision 3D devices on the CareLink Network offers patients peace of mind, knowing the device is constantly adjusting to the individual’s condition, and alerting me when a clinical change of concern has occurred so I can evaluate the patient’s situation and make appropriate treatment decisions,” said Prof. Dr. med. M. Zabel, Universitätsmedizin Göttingen der Georg-August-Universität in Göttingen, Germany.
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 27, 2007. Actual results may differ materially from anticipated results.